Key clinical point: Compared with adjuvant chemotherapy, adjuvant chemoradiotherapy is associated with improved survival in patients with resectable advanced gastric cancer.
Major finding: Adjuvant chemoradiotherapy significantly improved the overall survival (pooled hazard ratio [HR] 0.84; 95% CI 0.71-0.99) and disease-free survival (pooled HR 0.76; 95% CI 0.66-0.89). Neutropenia was the most common hematological toxicity. Nausea/vomiting was the most common gastrointestinal adverse event. Adjuvant chemoradiotherapy was associated with a higher risk for neutropenia (odds ratio 1.71; 95% CI 1.40-2.10).
Study details: This was a meta-analysis of 28 studies including 20,220 patients with resectable gastric cancer who received chemotherapy or chemoradiotherapy as adjuvant treatment.
Disclosures: This meta-analysis was supported by the Natural Science Foundation of Liaoning Province and Shenyang Science and Technology Plan, China. The authors declared no conflicts of interest.
Source: Lu H et al. Effect of chemoradiotherapy on the survival of resectable gastric cancer patients: A systematic review and meta-analysis. Ann Surg Oncol. 2022 (Jun 20). Doi: 10.1245/s10434-022-12005-1